Abstract BACKGROUND & AIMS Drug development for metabolic and alcohol-related liver disease and alcohol-related liver disease is emerging, but designing clinical trials remains challenging due to unknown disease progression rates and a lack of validated surrogate endpoints. We studied fibrosis progression rates and determinants of progression using dual liver biopsies and compared the prognostic performance […]
Fibrosis Progression Rate and Comparison of Paired Liver Biopsy vs Noninvasive Tests as Surrogate Endpoints for Clinical Trials in Metabolic and Alcohol-Associated Liver Disease and Alcohol-Associated Liver Disease.
May 14, 2026
Clin Gastroenterol Hepatol